{"entity":{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","aka":[],"tldr":"Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer.","summary":"Amanda Nickles Fader is a gynaecologic oncologist at Johns Hopkins. She was first author of the 2018 Journal of Clinical Oncology report of the randomised phase 2 trial in which adding trastuzumab to carboplatin and paclitaxel lengthened progression-free survival in advanced or recurrent HER2/neu-positive uterine serous carcinoma, a result that entered guidelines. Her research also covers minimally invasive surgery and rare gynaecological cancers.","asOf":"2026-09-18","links":[],"tags":["endometrial","gynaecological","trialist"],"related":[],"cancers":["endometrial-p53-abnormal","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-fader-trastuzumab-uterine-serous-jco-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic oncologist, Johns Hopkins","institutionId":"johns-hopkins","specialisms":["Uterine serous carcinoma","HER2-directed therapy","Minimally invasive gynaecologic surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fader%5BAuthor%5D"}],"papers":[]},"route":"/people/amanda-fader/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"paper":[{"id":"paper-fader-trastuzumab-uterine-serous-jco-2018","kind":"paper","name":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma","route":"/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/"}]}}